N/A N=39 Fetal and Neonatal Magnetophysiology
Fetal Arrhythmia · Abnormality in Fetal Heart Rate or Rhythm · Long QT Syndrome
Primary: Percentage of Subjects Experiencing Symptoms — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=90 Automated Fetal Heart Echocardiography by Five-Dimensional Ultrasound in the Third Trimester of Pregnancy
Fetal Heart Echocardiography by Five Dimensional Ultrasound
Primary: Number of Satisfactory Fetal Echocardiography Views by Two-Dimensional Ultrasound — 8.7 Number of satisfactory views
N/A N=234 Dysrhythmias During General Anesthesia in Children
Arrhythmias, Cardiac
Primary: Arrhythmias During General Anesthesia in Children — 220 participants
N/A N=71 Electrode-Based Sensor for Non-Invasive Fetal Heart Rate Monitoring With Improved Reliability
Laboring Women With Ultrasound and FSE Monitoring
Primary: Fetal Heart Rate Interpretability — 83.4; 62.4 percentage of time the signals are inter
N/A N=30 Maternal Fetal Device Performance Singleton
Pregnancy
Primary: Success Rate Calculated Based on Collection of Fetal Heart Rate Data From Investigational Devices on Subjects Enrolled in Each Gestational Age Group — 85.01; 92.27…
N/A N=11,108 Fetal ST Segment and T Wave Analysis in Labor
Pregnancy · Obstetric Labor · Parturition
Primary: Number of Participants With Primary Composite Outcome — 52; 40 Participants — p=0.20
Early Phase 1 N=103 Electrode-based Sensor for Non-invasive Fetal Heart Rate and EMG Monitoring With Improved Reliability
Pregnancy
Primary: Comparison of Electrode Sensor and TOCO Detection of Contraction Events, as Compared to IUPC — 2.98; 3.95 seconds
N/A N=35 Refinement of the OBMedical LaborView System
Fetal Monitoring
Primary: Fetal Heart Rate With the Laborview System Versus the CTG Monitor - Pilot Comparison Study — 5.282 beats per minute — p=<.1
N/A N=6,781 Use of Color Doppler in Routine Examination of Fetal Heart in Second Trimester
Congenital Heart Defects
Primary: Sensitivity of Color Doppler Examination to Detect Major Heart Defects During the Second Trimester of Pregnancy — 39; 9 fetuses
Phase 2 N=22 Pilot Randomized Trial With Flecainide in ARVC Patients
Arrhythmogenic Right Ventricular Cardiomyopathy
Primary: Number of Ventricular Ectopic Beats (VEBs) Per Day — 2685; 677 number of VEBs per day — p=<0.0001
N/A N=6 Heart Rate Variability and Prematurity
Premature Birth · Maternal Distress - Delivered · Stress
Primary: Feasibility: Acceptance (Ratio) — 33.3 percentage of <participants>
Phase 3 N=67 Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes
Pregnancy
Primary: Heart Rate — 146.0; 145.2; 142.5; 140.8 Beats per minute
N/A N=114 Oxygen for Intrauterine Resuscitation of Category II Fetal Heart Tracings
Electronic Fetal Monitoring · Fetal Hypoxia · Fetal-Placental Circulation
Primary: Mean Umbilical Artery Lactate at Delivery — 3.5; 3.4 mmol/L — p=0.69
N/A N=498 Diagnostic Accuracy of WEARable TECHnology Single-lead ECG in Detecting Cardiac Arrhythmias
Cardiac Arrhythmia · Atrial Fibrillation
Primary: Compare the Diagnostic Performance of Physician Rhythm Interpretation of 1-lead ECG Generated by SkyLabs CART-I Ring and Apple Watch Versus 12-lead ECG (Gold-standard)…
Phase 4 N=24 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit
Atrial Fibrillation
Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants
N/A N=19 Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment
Pregnancy · Drug Abuse
Primary: Fetal Heart Rate — 142.34 beats per minute
Phase 4 N=67 Heart Rate Regularization in Patients With Permanent Atrial Fibrillation Post Marketing Study
Permanent Atrial Fibrillation
Primary: Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE) — 32; 32; 15; 15 participants — p=<0.0001
N/A N=411 Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation
Heart Failure · Atrial Fibrillation
Primary: Composite of All-cause Mortality and Heart Failure Events — 50; 64 Participants
N/A N=100 A Study of Prolonged Electrocardiographic Monitoring in Patients With Heart Failure in Sinus Rhythm or Atrial Fibrillation
Heart Failure · Atrial Fibrillation
Primary: Number of Participants With an Identified Dysrhythmia on Baseline ECG Recording — 25; 35 Participants
N/A N=55 Medical Grade, Smartphone-based, Fetal Heart Rate Monitor for Outpatient Use
Pregnancy Related
Primary: Device Ease of Use — 72.8; 75.1 score on a scale — p=0.64
N/A N=80 The FARAPULSE PersAFOne III Trial for the Treatment of Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint: Composite Safety Endpoint (CSE) Defined as the Incidence of the Following Early-onset and Late-onset Serious Adverse Events (SAEs) Which Are…
N/A N=17 Evaluation of the Use of Apple Watch Features for Identification of Cardiac Arrhythmias
Atrial Fibrillation · Arrhythmias, Cardiac · Atrial Flutter
Primary: Atrial Fibrillation or Atrial Flutter (AF) of at Least 30 Seconds Duration — 0.11 Proportion of participants
N/A N=262 iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology
Atrial Fibrillation · Atrial Flutter
Primary: Rate of Recurrence of Atrial Arrhythmias — 0.132; 0.091 episodes per person-month of follow-up — p=0.05
N/A N=110 A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation
Atrial Fibrillation
Primary: Composite Endpoint: Atrial Arrhythmias Lasting >24 Hrs or Requiring Antiarrhythmic Drug Therapy; Need for Cardioversion/Repeat Ablation During the Study Period; Adverse…
N/A N=107 The Dynamics of Human Atrial Fibrillation
Atrial Fibrillation · Atrial Tachyarrhythmia
Primary: Survival Free of Atrial Fibrillation — 28; 31 participants
Phase 4 N=60 Heart Rate Response to Atropine Doses Less Than 0.1mg IV to Anesthetized Infants
Bradycardia · Arrhythmias
Primary: Incidence of Bradycardia — 0; 0 participants
N/A N=31 Characterising the Stable and Dynamic Left Atrial Substrate in Atrial Fibrillation
Atrial Fibrillation
Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV
N/A N=28 Feasibility Study of the FARAPULSE Endocardial Multi Ablation System in the Treatment of Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Safety at 30 Days — 1 Participants
N/A N=20 Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation(PersAFOne II)
Persistent Atrial Fibrillation
Primary: Composite Safety Endpoint;Proportion of Intent to Treat Subjects With One or More of the Specified Device or Procedure Related SAEs — 0 participants
Phase 3 N=523 Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation
Postoperative Atrial Fibrillation
Primary: Total Number of Days in Hospital — 5.1; 5.0 days — p=0.76